Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Fleischmann R, et al. Among authors: mysler e. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28. Arthritis Rheumatol. 2019. PMID: 31287230 Clinical Trial.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Genovese MC, et al. Among authors: mysler ef. Arthritis Rheum. 2008 Oct;58(10):2968-80. doi: 10.1002/art.23940. Arthritis Rheum. 2008. PMID: 18821691 Free article. Clinical Trial.
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C 3rd, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R. Genovese MC, et al. Among authors: mysler e. Arthritis Rheum. 2011 Oct;63(10):2854-64. doi: 10.1002/art.30463. Arthritis Rheum. 2011. PMID: 21618201 Free PMC article. Clinical Trial.
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R. Genovese MC, et al. Among authors: mysler e. J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584926 Free article. Clinical Trial.
Work instability in rheumatoid arthritis patients from Argentina: prevalence and associated factors.
Tamborenea MN, Pisoni C, Toloza S, Mysler E, Tate G, Pereira D, García Carrasco M, Quintero J, Cappuccio A, Granel A, Lazaro M, Arturi P, Citera G, Velazco Zamora J, Saurit V, Alvarellos A, Pons Estel SB, Danielsen C, Graf C, Paira S, Ceccatto F, Cavallasca J, Civit E, Moreno J, Estevez A, Diaz M, Verando M, Catalan Pellet A, Gomez G, Maid P, Beron A, Salvatierra G, Mendez M, Cusa A, Rillo O, Paez M, Larraude M, Sohn D, Gallo M, Conforti A, Malah V, Tate P, Baños A. Tamborenea MN, et al. Among authors: mysler e. Rheumatol Int. 2015 Jan;35(1):107-14. doi: 10.1007/s00296-014-3062-7. Epub 2014 Jun 20. Rheumatol Int. 2015. PMID: 24948375
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P. Weinblatt ME, et al. Among authors: mysler e. Arthritis Rheumatol. 2015 Oct;67(10):2591-600. doi: 10.1002/art.39249. Arthritis Rheumatol. 2015. PMID: 26138593 Clinical Trial.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Among authors: mysler e. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
80 results